Follow
'After positive results in clinical trials across cancer, metabolic and rare disease treatments, AstraZeneca’s share price has risen 19% in the past year and 140% in the last five years, valuing the company at nearly £189bn. This compares with Pfizer’s $227bn (£182bn).
AstraZeneca is now the largest company listed on the London Stock Exchange.'
